RYAM Q4 2025 Earnings Call Confirms Turnaround Headwinds Amid High Leverage

What happened

RYAM held its Q4 2025 earnings call, reinforcing previously guided weaker adjusted EBITDA of $135-140 million for the year, down from $222 million in 2024. Management highlighted ongoing cost-reduction efforts and biomaterials initiatives targeting over $300 million in run-rate EBITDA by 2027, but these remain aspirational against a backdrop of persistent GAAP losses. The call underscored significant balance sheet risks, with debt at $794 million, interest coverage at just 0.05x, and net debt/EBITDA around 3.5x, leaving little margin for error. While non-GAAP metrics were emphasized to portray operational progress, the company faces cyclical market pressures, declining cigarette-filter demand, and unresolved trade disputes that cap near-term pricing recovery. Investors should view the narrative with skepticism, as execution on cost savings and biomaterials is critical yet historically unproven, with liquidity thin and leverage high.

Implication

The Q4 earnings call confirms that 2025 EBITDA is stepping down significantly, reinforcing near-term earnings pressure and limiting valuation support despite optically cheap metrics. High debt and weak interest coverage amplify refinancing and covenant risks, making sustained positive free cash flow—targeted at $25-30 million for Q4—a critical but uncertain milestone. Execution on $30-50 million in cost cuts and biomaterials growth toward $31 million EBITDA by 2027 is essential for deleveraging, but past performance and external factors like tariffs suggest high probability of delays. Positive outcomes from trade cases could provide temporary relief, but structural declines in key markets and raw material volatility demand conservative assumptions about management's ambitious targets. Until clear evidence of leverage reduction and consistent profitability emerges, the stock warrants monitoring rather than investment, with downside risks outweighing speculative upside.

Thesis delta

The earnings call does not alter the core 'WAIT' thesis; it reaffirms the challenging outlook with guided EBITDA decline and persistent balance sheet strain. However, any incremental progress on cost savings or biomaterials could modestly improve confidence, yet significant execution and market risks remain unchanged, keeping the stance cautious.